COMPARISON OF FUNCTIONAL OUTCOMES IN EARLY VERSUS DELAYED ADMINISTRATION OF
ALTEPLASE FOR ACUTE ISCHEMIC STROKE IN THE EMERGENCY DEPARTMENT
A. McInerney, PharmD; J. Burkins, PharmD, BCPS; K. Fifer, PharmD, BCPS; M. McDowell, PharmD, BCCCP; C. Roels, PharmD, BCCCP; Nadine Lomotan, PharmD; D. Bhupali, MD;
M. Restraino, RN; D. Desai, PharmD, BCCCP
Pharmacy Department; Advocate Christ Medical Center; Advocate Aurora Health

PURPOSE
To determine whether alteplase door-to-needle time (<45
minutes vs >45 minutes) influences a patient’s functional status
at hospital discharge

BACKGROUND
• Stroke is the fifth most common cause of death and a leading cause
of disability in the United States

• Alteplase is an effective treatment for Acute Ischemic Stroke (AIS),
however its utility is diminished when there is a delay
in administration1,2
• Alteplase is a high-risk medication associated with
intracranial hemorrhage
• Administration of alteplase within 4.5 hours has shown
to correlate with improvement in in-hospital mortality
and functional outcomes at hospital discharge2-7
• With this known benefit, there continues to be a need to identify
the ideal administration window for optimization of patient
outcomes8,9
• A previous study found a significant association between
longer door-to-needle times (specifically > 45 minutes) and
increased in-hospital mortality and readmission rates8,10
• Currently, the rapid administration of alteplase is the focus
of many stroke centers, with a goal of < 45 minutes from
hospital arrival
• Even though administration of alteplase within 45 minutes
has shown mortality benefit in previous studies, it is
unknown whether this earlier administration of alteplase is
associated with an improvement in quality of life
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Baseline Characteristics

Primary Endpoint:
• Patient functional status at the time of hospital
discharge, measured by MRS

Secondary Endpoints:
• Barriers to early administration of alteplase:
• Unable to obtain medication history
• Delay in neuroimaging
• Unclear last known normal (LKN)
• Delay in obtaining consent
• Delay in receiving drug from pharmacy
• Blood pressure (BP) control
• Hospital Course: ICU/hospital length of stay
• Readmission: stroke/cardiac-related event

Safety Endpoints:
• Any intracranial hemorrhage (ICH)
• Symptomatic ICH
• In-hospital mortality rate
• Alteplase administered for stroke mimic

Reasons for Alteplase Delay

Demographics
<45 min
>45 min
Males, n(%)
38 (54.3)
33 (45.2)
Age (years), median [IQR]
66 [59-79]
63 [57-73]
NIHSS, median [IQR]
7 [4-15]
7 [4-13.5]
VAN positive, n(%)
37 (52.9)
43 (58.9)
Baseline mRS:
0, n(%) 54 (77.1)
64 (87.7)
1, n(%) 11 (15.7)
9 (12.3)
2, n(%)
5 (7.1)
0
Onset-to-arrival (min),
42 [27-71]
49 [33-95]
median [IQR]
Door-to-needle (min), median 35.5 [31-41] 63 [53-80]
[IQR]
Onset-to-needle (min),
79 [63-106] 119 [94-177]
median [IQR]
Large vessel occlusion, n(%)
41 (58.6)
51 (69.9)
Thrombectomy, n(%)
22 (31.4)
13 (17.8)
EMS hospital arrival mode,
58 (82.9)
54 (74.0)
n(%)

p-value
0.2776
0.2178
0.5587
0.7660
0.0449

0.0864
<0.0001
<0.0001
0.1588
0.0583
0.2486

• >18 years old
• Received alteplase
within 4.5 hours of
symptom onset for AIS
in the emergency
department (ED)

•
•
•
•

Pregnancy
Prisoners
mRS>2 at baseline
Patients without
documented mRS at
discharge

A total of 200 patients who presented to Advocate Christ Medical
Center ED between December 2018 – March 2022 were
identified. This sample size is based on feasibility.

Met inclusion criteria
(n=143)

> 45 min
(n=73)

13 (17.8) 0.0001
6 (8.2)
0.8092
30 (41.1) <0.0001
1 (1.4)
1.0000

14 (20)

21 (28.8)

0.2229

Outcome

<45 min

>45 min

p-value

Any ICH within 36h, n(%)

15 (21.4)

7 (9.6)

0.0498

Symptomatic ICH, n(%)

6 (8.6)

2 (2.7)

0.1601

Need for alteplase reversal,
n(%)
Stroke mimic, n(%)

3 (4.3)

1 (1.4)

0.3593

8 (11.4)

9 (12.3)

0.8679

Safety Outcomes

Limitations
Excluded Patients (n=57):
• Baseline mRS>2 (n=39)
• Alteplase received for inhospital stroke (n=16)
• Alteplase given for other
indication (n=1)
• Incomplete
administration (n=1)

• Retrospective chart review
• Single center study
• Feasibility study

Future Direction

Primary Outcome
Outcome
mRS at discharge:
<2, n(%)
>2, n(%)

• Continue data collection
<45 min

>45 min

22 (31.4)
48 (68.6)

23 (31.5)
50 (68.5)

p-value
0.9920

Secondary Outcomes
Outcome

< 45 min
(n=70)

p-value
0.0503

• No difference in functional outcome comparing early versus
delayed administration of alteplase
• Trend towards increased incidence of symptomatic ICH in early
administration group, with statistically significant increase of
any ICH
• Obtaining consent and neuroimaging were the biggest
contributors for delayed alteplase administration

Patient Enrollment

Patients who received
alteplase for AIS (N=200)

>45 min
10 (13.7)

CONCLUSIONS

Patients with AIS

IRB-approved, single center, retrospective, cohort study

<45 min
3 (4.3)
0
5 (7.1)
7 (10)
0

Vascular Risk Factors

RESULTS

METHODS

Reason
Obtaining medication
history, n(%)
Neuroimaging, n(%)
Unclear LKN, n(%)
Obtaining consent, n(%)
Receiving alteplase from
pharmacy, n(%)
Blood pressure control, n(%)

<45 min

>45 min

p-value

ICU LOS (days), median [IQR]

2 [1-3]

2 [1-3]

0.7594

Hospital LOS (days), median
[IQR]
Death in hospital, n(%)

4 [3-7]

4 [3-7]

0.3576

5 (7.1)

4 (5.5)

0.7416

Readmission for
stroke/cardiac-related events
within 90 days, n(%)

6 (8.6)

5 (6.9)

0.3720
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